---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-014618"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:57:36.523525+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex licenses exclusive patent rights to Reqorsa for glioblastoma from UTHealth Houston

## Summary
- Exclusive patent license with UTHealth Houston grants Genprex commercial rights to Reqorsa for GBM.
- Previous positive preclinical data (Oct 2024) showed Reqorsa reduced GBM cell viability and suppressed migration.
- TUSC2 tumor suppressor identified as novel target for glioblastoma by UTHealth Houston researchers.
- Company believes results support further in vivo evaluation in malignant glioma mouse models.

## SEC filing metadata
- accession: 0001437749-25-014618
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925014618/0001437749-25-014618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925014618/gnpx20250428_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-014618
- JSON: https://secwatch.observer/filing/0001437749-25-014618.json
- Plain text: https://secwatch.observer/filing/0001437749-25-014618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.